Abcam, ab270496, Human DPF2 knockout A-431 cell lysate

Size: 1Kit
DPF2 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9 X = 1 bp deletion Frameshift = 99.77%.
Key facts
Cell type:A-431,
Species or organism:Human,
Tissue:Skin,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 1 bp deletion Frameshift = 99.77%,
Disease:Epidermoid Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-DPF2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DPF2 also known as REQ is a protein that plays a role in chromatin remodeling an important process in gene expression regulation. The molecular weight of DPF2 is approximately 48 kDa. This protein is ubiquitously expressed in various tissues indicating its broad functional roles across different cell types. DPF2 participates actively in the modification of chromatin structure facilitating accessibility of DNA for transcription factors and other regulatory proteins.
Biological function summary
DPF2 acts as a component of the BAF complex which is a multi-subunit chromatin remodeling complex. The BAF complex modifies the structure of chromatin to regulate gene transcription affecting gene expression outcomes. DPF2 helps recruit other important proteins to the BAF complex contributing to the control of gene transcription dynamics during cell differentiation and development. Its function is essential in maintaining proper chromatin state which is important for cellular identity and function.
Pathways
DPF2 interacts significantly within the Wnt and Notch signaling pathways. In the Wnt pathway DPF2 contributes to the regulation of genes involved in cell proliferation differentiation and apoptosis. This protein also interfaces with related pathways by influencing the activity of other proteins such as beta-catenin in the Wnt pathway. In the Notch signaling pathway DPF2 modulates gene expression by affecting chromatin structure which influences cellular processes like proliferation and differentiation.
DPF2 has correlations with leukemia and other cancers. Abnormal expression or mutations of DPF2 possibly affect the balance of chromatin remodeling leading to misregulation of genes that control cell growth and survival. This protein potentially interacts with proteins such as MLL found in mixed lineage leukemia linking DPF2 to pathways that when dysregulated result in oncogenic transformation. Understanding DPF2's role in these disorders might offer novel therapeutic targets or diagnostic markers in oncology.